HEC169096 in Participants With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2027-08-30
Target enrollment:
Participant gender:
Summary
An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability,
Pharmacokinetic Characteristics And Effectiveness Of HEC169096 In Patients With Thyroid
Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors.